Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA 1 5 30 versus NORTREL 1 35 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA 1 5 30 versus NORTREL 1 35 28.
AUROVELA 1.5/30 vs NORTREL 1/35-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin (FSH, LH) release via negative feedback on pituitary; norethindrone acetate inhibits ovulation by suppressing LH surge, altering cervical mucus and endometrial lining.
Combination of ethinyl estradiol and norethindrone inhibits gonadotropin secretion via negative feedback on the hypothalamic-pituitary-ovarian axis, suppressing ovulation. Additionally, increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (1.5 mg norethindrone acetate, 30 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.
One tablet (norethindrone 1 mg + ethinyl estradiol 35 mcg) orally once daily for 28 days, followed by a 7-day placebo period (if using 28-day pack) or continuous if using 21-day pack with 7-day off. Start on first day of menstrual period.
None Documented
None Documented
Norethindrone: 8-10 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved within 5-7 days.
Norethindrone: 5-14 hours (terminal); ethinyl estradiol: 13-27 hours (terminal). Context: steady-state after 5-7 days; dose adjustment in hepatic impairment.
Renal (25% norethindrone metabolites, 5% ethinyl estradiol metabolites) and fecal (60% norethindrone, 30% ethinyl estradiol); <1% unchanged drug in urine.
Renal 60-70% (as glucuronide and sulfate conjugates), fecal 20-30% (via biliary excretion).
Category C
Category C
Oral Contraceptive
Oral Contraceptive